| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5842828 | Life Sciences | 2012 | 10 Pages |
Abstract
In conclusion, Nebivolol showed no benefit after 6Â weeks in rapidly progressing, ANG II-dependent 5/6 A/I model of chronic kidney disease. This contrasts to the protection seen with 6Â month treatment of Nebivolol in the slowly progressing 5/6 ablation model.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jennifer M. Sasser, Natasha C. Moningka, Tatsiana Tsarova, Chris Baylis,